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INCREASED EXPRESSION OF ARTHRITIC MARKER GENES IN THE
CARTILAGE OF SIRT1 NULL MICE
O.H. Gabay1, E. Lee1, R. Booth1, V. Gagarina1, M. Dvir-Ginzberg2, D.J. Hall1
1NIH, Bethesda, MD; 22Lab. of Cartilage Biology, Inst. of Dental Sci., Faculty of
Dental Med., The Hebrew Univ. Hadassah Ein Kerem, Jerusalem, Israel
Purpose: Osteoarthritis (OA), the most frequent age related disease present
in the west, is a multi-factorial imbalance between cartilage anabolism and
catabolism. To understand the mechanisms underlying OA, we focused on
the protein deacetylase SirT1, a factor known to prolong organism lifespan.
SirT1 has been previously shown to regulate apoptosis and cartilage-
speciﬁc gene expression in human chondrocytes. Recent data also indicates
that SirT1 is a potent inhibitor of the matrix metalloproteinases (MMPs).
MMPs are the most well known of arthritis marker genes that play a
central role in cartilage degeneration. In order to evaluate the role of SirT1
in cartilage homeostasis, we assessed MMP and ADAMTS expression in the
cartilage of SirT1 null mice.
Method: We used SirT1 Wild-type (WT) and SirT1 Null mice in the analysis.
The SirT1 Null mice do not express SirT1. Articular cartilage was harvested
from hind paws in 1 to 3 week old mice. The cartilage was processed for
both immunohistochemistry and subculture of chondrocytes.
Results: Articular cartilage tissue sections from SirT1 Null mice exhibited
low levels of type 2 collagen, aggrecan and glycosaminoglycans (GAG)
compared to SirT1 WT mice at 1 week or 3 weeks. Protein levels of
aggrecan and type 2 collagen were also decreased in the chondrocytes
derived from SirT1 Null mice. In contrast, protein levels of MMP-3, MMP-8,
MMP-9 and MMP-13 were elevated in the SirT1 Null mice compared to
WT. Finally, DBC1 (deleted in breast carcinoma 1), a known Sirt1 associated
protein that represses SirT1 enzymatic activity, was found to be elevated in
the SirT1 Null mice compared to WT.
Conclusion: The data from this animal model indicate that SirT1 is
a negative regulator of the genes responsible for cartilage degradation
in arthritis; namely the MMPs and DBC1. The role of SirT1 as a pu-
tative anti-arthritic gene is consistent with its general function as an
anti-aging/anti-inﬂammatory protein.
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PHARMACOLOGY OF THE STR/ORT MOUSE AS A MODEL FOR
OSTEOARTHRITIS: RESPONSIVENESS TO EP4 ANTAGONISTS AND
AGGRECANASE INHIBITORS
R. Chiusaroli, P. Larger, C. Falcioni, A. Grotti, M. Lanza, L.P. Stasi, L.C. Rovati,
G. Caselli
Rottapharm S.p.A, Monza, Italy
Purpose: The STR/ort mice develop spontaneous osteoarthritis (OA) of the
knee, and are believed to be a relevant model for human knee OA. We have
recently shown that treatment with either glucosamine sulfate or an MMP
and aggrecanase inhibitor reduced the severity of the OA histological score
as well as histomorphometric parameters in this strain. To further validate
this model for drug discovery purposes, we investigated its responsiveness
to further interventions within strategies currently pursued for OA treat-
ment. We investigated in two separate studies the effects of an EP4 speciﬁc
antagonist, or of a speciﬁc aggrecanase inhibitor, respectively, in STR/ort
mice.
Methods: As a speciﬁc EP4 receptor antagonist we used CJ-042,794
(Murase et al., 2008). Wyeth’s compound #8OO described in patent WO
2007/008994 was used as an aggrecanase1/2 speciﬁc inhibitor (ASI).
STR/ort male mice were recruited at 5 months of age (n=20-22). Com-
pounds were administered orally once daily for 3 months, 3 and 30 mg/kg
CJ-042,794, and 60 and 150 mg/kg ASI; vehicle was 0.1% methocel for both
experiments. At the end of treatment, the animals were euthanized and the
knee joints collected, processed for histology and blindly scored according
to both Mankin’s and the OARSI method. Statistical analysis was performed
by the Student’s t test or by ANOVA followed by Dunn’s or Dunnett’s tests
comparing all treatment groups vs. vehicle.
For both compounds the plasma levels were monitored in limited phar-
macokinetic studies in the STR/ort mouse to conﬁrm the exposure at
pharmacological relevant concentrations.
Results: After three months of daily treatment, vehicle-treated animals
displayed severe OA with clefting and erosion of the articular cartilage
to the subchondral bone, with prominent chondroosseous metaplasias and
often inﬂammation and pannus. No improvement whatsoever was associ-
ated with treatment with the EP4 antagonist CJ-042,794 at either dose, at
least in histopathological parameters, despite the animals were exposed to
circulating levels well above its IC50 [approx. 10 nM] on EP4 receptors (e.g.,
3 h after administration plasma concentration was 15 μg/ml [35 μM]).
Conversely, we observed a signiﬁcant albeit slight decrease of OARSI score
and total score following treatment with the ASI, at the higher dose (200
mg/kg). Pharmacokinetic analyses for ASI (Cmax=102 μg/mL [214 μM], T1/2
=2h, AUC 0-24h=198 μg.h/mL), conﬁrmed that these animals were exposed
to circulating levels above the aggrecanase inhibiting concentrations [92
nM and186 nM vs. aggrecanase 1 and 2, respectively).
Conclusions: The present studies conﬁrm the STR/ort mouse as a model of
choice for evaluating OA disease modifying drugs. Moreover, they further
establish aggrecanase inhibition as a disease-modifying approach, while
suggest that EP4 antagonism is mainly an OA pain-controlling strategy.
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STRENUOUS RUNNING AS A MODEL FOR OSTEOARTHRITIS IN RATS:
ANALYZED USING CONTRAST ENHANCED MICROCT
M. Siebelt, E. Waarsing, N. Kops, J.A. Verhaar, H. Weinans
Erasmus MC, Rotterdam, Netherlands
Purpose: Both to enhance basic knowledge of osteoarthritis (OA) develop-
ment and to test the effect of disease modifying OA drugs (DMOADs), a
large need for proper (small) animal models exists. Mostly, these models
make use of either enzymatic or chemical intra-articular injections or
surgical induced instability.
In 1998 a model for OA was described that induced OA in rats through
strenuous exercise evoked by intra-cranial stimulation. This model has
been modiﬁed using a (more practical) rodent treadmill with electric shock
stimuli to force running for a period of six weeks. Several studies have used
this model to study the effect of different DMOADs.
The goal of the current study was to investigate which early signs of
OA could be detected using in-vivo contrast-enhanced microCT (CECT) in
Wistar rats that were forced to run for 30 kilometres over a six week
period. Second, we investigated if the induced OA was progressive after the
running stimulus was stopped after six weeks.
Methods: Six male Wistar rats were trained for one week to run in a rodent
treadmill machine as follows: day 1, 10 minutes at 0.60 km/hr; day 2 15
minutes at 0.72 km/hr; day 3 20 minutes at 0.90 km/hr; day 4 30 minutes
at 1.08 km/hr and day 5 35 minutes at 1.20 km/hr. The following 5 weeks,
the rats were forced to run for ﬁve days a week, the ﬁrst 10 minutes at 0.72
km/hr in order to warm-up and the following 50 minutes at 1.20 km/hr.
All knee joints of all animals were scanned with CECT at the start of the
experiment (t = 0) and directly after running at t = 1, 3, 6 weeks. After 70μl
intra-articular injection with ioxaglate into their knee joint, the negative
charged contrast agent (ioxaglate) enabled to measure both quantitative
(volume) and qualitative (GAG-content) changes in cartilage tissue over
time. At six weeks the running exercise stopped, a subsequent CECT scan
was performed at 12, 18 and 24 weeks. In this abstract we present all
CECT-data for condylar, patellar and trochlear cartilage up to 12 weeks
follow-up.
Results: After three (p=0.02) and six weeks (p=0.01) of running signiﬁ-
cant higher attenuation values were detected, indicating GAG loss from
condylar cartilage. At 12 weeks (6 weeks after running was stopped)
the total volume of condylar cartilage was signiﬁcant reduced, indicating
OA progression (p=0.02) (Figure 1). Patellar cartilage attenuation was not
Figure 1. Condyle.
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Figure 2. Patella.
Figure 3. Trochlea.
increased, but its volume was reduced after three weeks of running,
becoming signiﬁcant after 12 weeks (p=0.0007) (Figure 2). Attenuation
was signiﬁcantly increased in trochlear cartilage at 12 weeks (p=0.009),
although not signiﬁcant, trochlear cartilage volume showed a clear trend of
reduction from one to 12 weeks (Figure 3).
Conclusions: With CECT we successfully analyzed OA progression in knee
joints of strenuous running Wistar rats. Our data suggests that 6 weeks of
running damages cartilage beyond the ability for repair, which results in
OA progression even when rats are not forced to run anymore. In addition,
we demonstrate that besides disease progression at the weight-bearing
condyles, the articular cartilage of the femoral bone and the patella is also
affected. Our ﬁndings demonstrate that this model could very well be used
for testing DMOADs, also after the OA inducing running stimulus has been
stopped. In such a study, (regenerative) compounds can be tested without
the stimulus inducing OA and counteracting a possible positive effect of the
studied drug.
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TREATMENT WITH AN AGGRECANASE SPECIFIC INHIBITOR AND LUBRICIN
SIGNIFICANTLY REDUCES JOINT PAIN IN A RAT MODEL OF
POST-TRAUMATIC ARTHRITIS
M.A. Rivera-Bermudez, J. Tejada, T.J. Blanchet, S. Soucy, L. Savary,
K. Georgiadis, C.R. Flannery, S.S. Glasson
Pﬁzer, Cambridge, MA
Purpose: Traumatic joint injuries lead to an increased incidence of acceler-
ated and progressive loss of the normal structure and function of articular
cartilage, resulting in pain and signiﬁcant disability. The rat meniscal tear
(MT) model of post-traumatic arthritis (PTA) is a primary in vivo system for
testing the ability of potential therapeutics to slow cartilage degradation
and pain following acute injury. It has previously been demonstrated that
treatment with either an aggrecanase speciﬁc inhibitor (ASI) or recom-
binant lubricin is chondroprotective in the rat MT model. In the current
study, we evaluated the effect of treatment with ASI and Lubricin, either
dosed separately or in combination, on pain in this model.
Methods: All in vivo experimental procedures were IACUC reviewed and
approved. Male Lewis rats underwent medial MT surgery on the right knee
to induce joint instability. Study #1: rats were dosed with vehicle, 60
mg/kg/day ASI (PO, starting on the day of surgery), 20 μg of intra-articular
(IA) recombinant lubricin (LUB1; 3X/week, starting one week post-surgery)
or combined dosing with both ASI and LUB1. Dosing was terminated
5 weeks post-surgery. Study #2 replicate the dosing paradigm in study
1, but at 5 weeks post-surgery, dosing ceased and the study continued
for an additional 5 weeks. The change in hind paw weight distribution
between the ipsilateral knee and contra-lateral knee was measured with
an incapacitance meter (Linton, CO) at various time points.
Results: Treatment with ASI and LUB1 signiﬁcantly reduced pain 4 weeks
after surgery. Moreover, combination therapy of ASI and LUB1 proved more
eﬃcacious than either therapy alone. Both ASI and LUB1 continued to
ameliorate pain at 2 and 3 weeks after dose cessation.
Conclusions: The present study demonstrates that ASI and LUB1, both
separately, and to a greater extent in combination, have the potential to
signiﬁcantly reduce joint injury-associated pain during the progression of
PTA. Treatment with ASI and LUB1 alone also proved eﬃcacious in reducing
pain 3 weeks after dose termination, suggesting that the effect on pain
can be prolonged for a substantial period after ASI and LUB1 treatment
cessation. These results support the development of ASI and LUB1 as
potential therapies following joint injuries in humans, to provide both pain
relief as well as chondroprotection.
098
USE OF GAIT ANALYSIS AS AMEASURE OF SPONTANEOUS PAIN BEHAVIOR
IN MURINEMODELS OF ARTHRITIS
C. Dorman1, H.E. Krug2,1, S.R. Anderson2, S.V. Frizelle1, M.L. Mahowald2,1
1VA Med. Ctr., Minneapolis, MN; 2Univ. of Minnesota, Minneapolis, MN
Purpose: Murine models of arthritis are important tools for the study of
arthritis pain and discovery of new analgesic therapies, however measuring
pain in mice can be challenging. We have previously described sensitive
and speciﬁc methods for measuring evoked pain behaviors in mice with
acute and chronic arthritis pain. But it is also desirable to incorporate the
measurement of spontaneous behaviors that are sensitive to change with
pain and analgesia. We have used two methods of digitized gait analysis to
detect changes in spontaneous gait behavior in order to quantify pain in
murine models of arthritis and to detect analgesic responses.
Methods: C57Bl6 mice were used for all experiments. In all cases arthritis
was produced only in the left knee. Chronic arthritis was produced by IA
injection of 10 IU Collagenase. Acute inﬂammatory arthritis was produced
by IA injection of 10 μl 3% carrageenan. Analgesia was provided by
Botulinum toxin type A (BoNT/A) (0.02 IU) which was given IA into the
left knee 3 days before testing. The normal right knee served as internal
nonpainful control. Mice were studied in the naïve pre-arthritic state, after
induction of arthritis and after IA BoNT/A or saline control treatment.
Video gait analysis was performed using DigiGait™ (Mouse Speciﬁcs, Inc,
Quincy, MA) hardware and software and TreadScan digitized gait analysis
system (Clever Sys, Inc. Reston, VA) Evoked pain behavior was measured by
tallying ﬁghts + vocalizations/1 min in response to repeated ﬁrm palpation
of the knee preformed by a single, trained examiner. Strength was observed
visually and graded semiquantitatively as ability to grasp and cling to
a wire grid. Visual assessment of gait was also performed and similarly
graded. Student’s t-test was used for statistical comparisons.
Results: No mouse appeared weak as a result of BoNT/A injection. Arthritis
pain was clearly and reproducibly indicated by increased Evoked pain
scores in both acute inﬂammatory and chronic noninﬂammatory arthritic
mice. Analgesia after BoNT/A injection was modest in acute inﬂammatory
arthritis and did not reach statistical signiﬁcance. Anagesia after BoNT/A
was statistically signiﬁcant in mice with chronic arthritis as measured by
Evoked pain scores. Although gross abnormalities of gait could be seen by
visual observation in arthritic mice, speciﬁc alterations in gait parameters
were less common, of small magnitude, and somewhat inconsistent. Similar
results were obtained using two different gait analysis systems. As might
be expected in a quadruped, alterations in gait due to pain did not appear
to be conﬁned to the arthritic limb, but these results were not consistent.
Evoked Pain Response - Left Knee
Mean (SEM) Non-Arthritic Arthritic BoNT/A Rx Saline Rx
Chronic Non-Inﬂammatory Arthritis 2.0 (0.76) 8.2 (1.22) 4.5 (1.04) 8.2 (2.39)
Acute Inﬂammatory Arthritis 1.3 (0.49) 12.8 (3.41) 6.1 (1.21) 10.0 (2.69)
Conclusions: Pain can be quantitated in murine models of arthritis using
visual and computerized gait analysis, and evoked pain scores. Evoked
pain responses increased signiﬁcantly with arthritis and decreased with IA
BoNT/A and appear to be reliable and reproducible. No limb weakness was
noted. Although gross changes in gait can be seen in animals with arthritis,
detection by digitized gait analysis is subject to individual variation, and
